Latest Conference Coverage

Dose-Dependent Weight Reductions Observed With Atogepant

In the open-label extension where the highest dose of atogepant (Qulipta; AbbVie) was observed, 24.1% of participants had at least 7% weight loss compared with 14.7% of those on standard of care.

The Effect of Mindfulness Practices on Migraine: Paige Estave, PhD

The MD-PhD student at Wake Forest School of Medicine shared her perspective on the findings of a study suggesting that mindfulness practices can alter pain perception and migraine attack awareness, among other results. [WATCH TIME: 4 minutes]

NeuroVoices: Tanuja Chitnis, MD, on Targeting Anti-CD3, Other Biomarkers in Progressive Multiple Sclerosis

The associate neurologist at Brigham and Women’s Hospital discussed the potential of a nasal anti-CD3 monoclonal antibody, foralumab, and its impact on biomarkers specific to patients with progressive multiple sclerosis.

2022 SMA Research & Clinical Care Meeting: What to Expect

Mary Schroth, MD, and Jacqueline Glascock, PhD, of Cure SMA, share their perspectives on the upcoming annual meeting.

Children, Adolescents With Migraine Show High Risk for Anxiety and Depression Symptoms

A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.

Need for Improved Access to and Interventions for Mental Health in Multiple Sclerosis: Louise Palmer, MA

The health research assistant at the Shepherd Center discussed the importance of interventions that address mental health for patients with multiple sclerosis, including counseling and support groups. [WATCH TIME: 2 minutes]

Exposing Young Professionals to Multiple Sclerosis Care, Interdisciplinary Teams: Stephanie Teixeira-Poit, PhD

The associate professor at the North Carolina Agricultural and Technical State University discussed a newfound initiative that helps encourage more professionals in multiple sclerosis and across neurology. [WATCH TIME: 4 minutes]

Investigational DHE Nasal Powder STS101 Shows Tolerability in Phase 3 Study

The most common adverse events reported by individuals using the dihydroergotamine nasal powder were nasal discomfort, dysgeusia, and nasal congestion, all of which were mild and transient in nature.

CGRP Monoclonal Antibodies Show No Significant Impact on Persistent Headaches in Idiopathic Intracranial Hypertension

Secondary outcomes, assessed by the change in the number of monthly headache days by at least 25%, 75%, or 100%, were also not significant following treatment with CGRP monoclonal antibodies.

The Endocannabinoid System and its Relationship to Migraine: Tally Largent-Milnes, PhD

The assistant professor of pharmacology at the University of Arizona College of Medicine Tucson shared her insight into the endocannabinoid system and its therapeutic potential in treating migraine. [WATCH TIME: 5 minutes]

Final Thoughts and Takeaways on MS DMT Discontinuation

Neuronal Complexity in a Model of Migraine: Amynah Pradhan, PhD

The associate professor of psychiatry at the University of Illinois at Chicago shared the findings of her and colleagues’ work that suggest that distinct cytoarchitectural changes occur in the brain that may underlie migraine chronification. [WATCH TIME: 4 minutes]

Women of Reproductive Age Likely Underdiagnosed With Migraine in the ED Setting, Particularly Black and Hispanic Women

Data from a cohort of almost 5000 women seen at Montefiore Health System emergency departments suggest that primary headache, likely migraine, is underdiagnosed, and a high proportion of these women being of Black and Hispanic backgrounds.

Anxiety and Depression in Children and Adolescents With Migraine: Serena L. Orr, MD, MSc

The pediatric neurologist and headache specialist at the University of Calgary discussed the work she presented at AHS 2022 on the incidence of anxiety and depressive disorders in the pediatric migraine population. [WATCH TIME: 6 minutes]

Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence

Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.

The DISCO-MS Study Findings and Clinical Experience

Benefits Observed With Second Dose of Eptinezumab in Chronic, Episodic Migraine

The percent change in monthly migraine days across weeks 1 to 12 and scores on Headache Impact Test were precursors to suboptimal response to eptinezumab, prompting the need for a second dose.

Assessing the Correlations With Sleep Issues and Risk of Dementia: Ruth Benca, MD, PhD

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine provided insight on the signs and risks associated with sleep disorders and Alzheimer disease. [WATCH TIME: 3 minutes]

Ubrogepant Sustains Efficacy, Safety in Combination With OnabotulinumtoxinA

At 2- and 4-hours post dose, return to normal function was achieved by 30.1% and 52.1% of participants for their first 10 ubrogepant-treated attacks.

Schooling Changes During COVID-19 Pandemic Suggestive of Improved Headache Coping Ability for Pediatric Patients

Headache frequency remained the top driver of higher disability scores, but opposing to prior findings, school versus summer was not a significant predictor of disability, suggesting that pandemic schooling changes affected coping abilities to cause less disability.

Hypothesis and Reasoning of the DISCO-MS Study

Advantages With Extended Release Glatiramer Acetate in Relapsing, Progressive MS: Ehud Marom

The president and chief executive officer of Mapi Pharma discussed the differences and additional benefits from glatiramer acetate depot, a new intramuscular extended-release version of the known multiple sclerosis medication. [WATCH TIME: 4 minutes]

The Incidence of and Difficulties in Defining Status Migrainosus: Rashmi Halker Singh, MD, FAHS, FAAN

The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]

The MiCOAS Project and the Importance of Patient-Reported Outcomes in Migraine

The director of the Montefiore Headache Center spoke about the Migraine Clinical Outcome Assessment System project and the need for better patient-reported outcome measures in migraine clinical care.

Anecdotal Evidence and the Need for Trials of Psychedelics in Headache Disorders: Bryan Roth, MD, PhD

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]

Rimegepant Is Well-Tolerated and Safe for Migraine Over 1 Year With Every-Other-Day Dosing

Patients in the open-label extension also showed limited need for acute treatment with rimegepant (Nurtec ODT; Biohaven Pharmaceuticals), as more than 80% of patients took 16 or fewer total tablets over the 28-day period.

The Need for Effective Treatments for Status Migrainosus: Matthew Robbins, MD

The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the hot topics at the American Headache Society Annual Scientific Meeting, including a presentation on the prevalence of status migrainosus. [WATCH TIME: 4 minutes]

Monoclonal Antibodies, Gepants, and Triptans Show Little Differences in Possible Response Predictive Variables

A retrospective review of more than 1000 electronic medical records suggests that for those with migraine, the presence of neck pain, anxiety, depression, and insomnia show no comparative differences in treatment response predictability.

Assessing Psychedelics for Therapeutic Potential in Cluster Headache: Bryan Roth, MD, PhD

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine shared his insight into his keynote address at the American Headache Society Annual Scientific Meeting. [WATCH TIME: 8 minutes]

Remaining Questions Surrounding COVID-19 Vaccines in MS